387 related articles for article (PubMed ID: 6607976)
1. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
[TBL] [Abstract][Full Text] [Related]
2. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
4. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
5. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin.
Vaishnavi K; Bansal D; Trehan A; Jain R; Attri SV
Pediatr Blood Cancer; 2018 Dec; 65(12):e27241. PubMed ID: 29768710
[TBL] [Abstract][Full Text] [Related]
6. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
[TBL] [Abstract][Full Text] [Related]
7. The prevention of methotrexate toxicity by thymidine infusions in humans.
Ensminger WD; Frei E
Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
[TBL] [Abstract][Full Text] [Related]
8. High-dose leucovorin as sole therapy for methotrexate toxicity.
Flombaum CD; Meyers PA
J Clin Oncol; 1999 May; 17(5):1589-94. PubMed ID: 10334548
[TBL] [Abstract][Full Text] [Related]
9. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.
van den Bongard HJ; Mathĵt RA; Boogerd W; Schornagel JH; Soesan M; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2001 Jun; 47(6):537-40. PubMed ID: 11459208
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study.
Parker LM; Griffiths CT; Yankee RA; Knapp RC; Canellos GP
Cancer Treat Rep; 1979 Feb; 63(2):275-9. PubMed ID: 312692
[TBL] [Abstract][Full Text] [Related]
11. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic agents: high-dose methotrexate and citrovorum factor rescue.
Sadée W
Ther Drug Monit; 1980; 2(2):177-85. PubMed ID: 6762711
[TBL] [Abstract][Full Text] [Related]
13. [High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma].
Sampi K; Hattori M
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1068-73. PubMed ID: 6985194
[TBL] [Abstract][Full Text] [Related]
14. The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients.
Reggev A; Djerassi I
Cancer; 1988 Jun; 61(12):2423-8. PubMed ID: 3259154
[TBL] [Abstract][Full Text] [Related]
15. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
16. [Severe renal impairment of methotrexate elimination after high dose therapy].
Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
[TBL] [Abstract][Full Text] [Related]
17. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
18. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate.
Yang SL; Zhao FY; Song H; Shen DY; Xu XJ
ScientificWorldJournal; 2015; 2015():751703. PubMed ID: 26185782
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
